Close Menu

NEW YORK (360Dx) – A new mass spectrometry blood test from Quest Diagnostics aims to provide physicians with an easy tool for assessing insulin resistance as an early predictor of future diabetes.

The test, called the Cardio IQ Insulin Resistance Panel with Score, has been offered for about two months through Quest and is performed at Quest's Nichols Institute in San Juan Capistrano, California.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.